Authors
Latest:
Minimizing the Risk of Mistakes in HTAWe all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at similar mistakes made in the past and what can be done about them.
Latest:
HCP Giveaways: Get RealThe Patient Protection and Affordable Care Act (?PPACA?) requires manufacturers to record, aggregate and report to the federal government ?payments and other transfers of value? to a covered recipient. This article will focus on the two key convention-related items under PPACA: food and educational products.
Latest:
The New Metrics of Market SuccessProfitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?
Latest:
Time to Appoint a 'Chief Patient Officer'?Sarah Krug asks if it is time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust.
Latest:
Recommendations for Accelerating Cell and Gene TherapiesWhile there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.
Latest:
Manage yourself to successThe most successful sales representatives don't wait to be empowered by their manager - they empower themselves.
Latest:
Sharing IP, Sharing RiskThanks to growth in international trade, rapid technological innovation, and a willingness to share intellectual property (IP), the number of corporate cross border alliances has grown steadily.
Latest:
Gottlieb is Stepping Down From the FDA’s Most Forward-Looking ChapterWe’re about to lose the most tech-savvy FDA chief in recent memory, writes Pratap Khedkar.
Latest:
Mixed Criticism on Avandia EffectivenessGSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.
Latest:
Why Use a Clinical Data Warehouse?An increasing pressure to get products to market means more data must be handled within a shorter time span. But how?
Latest:
Three Challenges to CRO SuccessThe last few years have seen tremendous consolidation in both the pharmaceutical and contract research industries. The impact among pharma companies has created a heightened demand for productivity. Consequently, contract research organizations (CROs) have struggled to find their footing in a business where the number of customers has shrunk and the demand for speed and cost-effectiveness has risen. Delivering service excellence when customers' names and addresses are changing regularly is a challenge, resulting in disrupted continuity, broken lines of communication, and policies and relationships thrown into disarray.
Latest:
What pharma can learn from general manufacturing in a recessionWhile pharma is not synchronized with the boom and bust of the general economy, lessons from the business cycle facing manufacturers can enable the pharmaceutical industry to tackle the problems it faces, writes Chris Hart of McKinney Rogers.
Latest:
Personalized Medicines: Implications for PharmaMarketers will need to address not only the benefits of the therapy but also the benefits of a diagnostic assay.
Latest:
Why Use a Clinical Data Warehouse?An increasing pressure to get products to market means more data must be handled within a shorter time span. But how?
Latest:
Four Launch Mistakes and How to Avoid ThemIn the white heat of a major brand launch, we can be consumed by the day to day challenges and make mistakes. But some of the worst mistakes can be avoided with a little foresight, writes Ken Begasse.
Latest:
What's Really Driving Costs?According to many legislators and the media, pharma companies, abetted by Madison Avenue, lead the corporate villain list, just below auditors and errant CEOs.
Latest:
Pharma 2016: Hot Topics, Burning QuestionsPharm Exec Editorial Advisory Board member Cliff Kalb poses some of the pertinent questions he expects the pharma industry will be asking this year.
Latest:
Supreme Court Gets Final Say on OvertimeWith conflicting lower court decisions over whether pharmaceutical sales reps should be paid for overtime, the Supreme Court has agreed to settle the matter. The court will hear the case brought by two former GSK reps that were denied their overtime claim by a Circuit Court.
Latest:
The future of phamaceutical sales training: Internet as instructorLearning and training from home is just around the corner.
